Plain-English translation of NCT06947746 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing (human induced Sertoli-like cells)—a new type of cell-based treatment—given as a single injection directly into an affected knee joint. The study wants to see if this injection is safe, well-tolerated, and can help reduce pain and swelling in people with rheumatoid arthritis. Researchers will follow participants for 24 weeks after the injection to measure how well the treatment works.
Many people with rheumatoid arthritis continue to experience pain and swelling in their joints even after taking standard medications for several months. This trial explores whether this new cell-based treatment could offer relief to patients whose current drugs aren't working well enough.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive a single injection of the new cells directly into your affected knee joint at the study center. You will then have follow-up visits over 24 weeks (about 6 months) so the doctors can check your pain, swelling, and any side effects. During this time, you will continue taking your regular arthritis medications as prescribed. The study involves a small group of 15 participants at a single hospital location in Shanghai.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China
Sponsor
Shanghai Changzheng Hospital
Enrollment target
~15 participants
Started
May 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huji Xu, Ph.D, MD
Shanghai Changzheng Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.